Login to Your Account

Innocoll kicks Cogenzia to curb on failed trials, submits Xaracoll NDA

By Michael Fitzhugh
Staff Writer

Friday, November 4, 2016

The failure of a gentamicin-containing collagen sponge called Cogenzia to deliver statistically significant improvements in clinical cure rates for patients with diabetic foot infections during twin phase III studies sunk shares of Innocoll Holdings plc on Friday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription